



ESMO VIRTUAL PRECEPTORSHIP

23-24 OCTOBER 2020

Co-Chairs

Andrés Cervantes, Spain Florian Lordick, Germany

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

23-24 October 2020

CO-CHAIRS: Andrés Cervantes, Spain

Florian Lordick, Germany

SPEAKERS: William Allum, United Kingdom

Maria Alsina, Spain Fatima Carneiro, Portugal Valentina Gambardella, Spain Karin Haustermans, Belgium Elizabeth Smyth, United Kingdom

LEARNING OBJECTIVES

- To learn about the fundamentals of pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with 6 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org

www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Friday, 23 October 2020

15:00-15:10 10'	Opening and welcome	
10'	Welcome from ESMO and introduction	Andrés Cervantes, ES
15:10-17:20 130'	SESSION 1 Localized gastroesophageal adenocarcinomas	Moderator: Andrés Cervantes, ES
25'	Pathology assessment of gastric and junctional adenocarcinomas	Fatima Carneiro, PT
25'	The role of surgery in localized gastric and junctional cancers	William Allum, UK
25'	Developments in radiotherapy for localized gastric and junctional cancers	Karin Haustermans, BE
10'	Discussion	Faculty
16:35-16:45	Break	
25'	Neoadjuvant and adjuvant therapy for localized gastric and junctional cancers	Elizabeth Smyth, UK
10'	Discussion	Faculty
17:20-18:20 60'	SESSION 2 Cases discussion of localized disease	Moderator: Andrés Cervantes, ES
4x15'	4 x Participants clinical case discussion	Faculty

Saturday, 24 October 2020

15:00-17:10 130'	SESSION 3 Treatment for advanced gastroesophageal adenocarcinomas	Moderator: Florian Lordick, DE
20'	First line treatment for HER2 non amplified advanced gastroesophageal adenocarcinomas	Florian Lordick, DE
20'	Treatment for HER2 amplified and advanced gastroesophageal adenocarcinomas	Andrés Cervantes, ES
20'	Second line treatment and beyond for advanced gastroesophageal adenocarcinomas (including chemo and targeted agents)	Maria Alsina, ES
10'	Discussion	Faculty
16:10-16:20	Break	
20'	The use of Immunotherapy after first line in advanced gastroesophageal adenocarcinomas	Elizabeth Smyth, UK
20'	Looking for precision medicine in advanced gastroesophageal adenocarcinomas	Valentina Gambardella, ES
10'	Discussion	Faculty

17:10-18:10 60'	SESSION 4 Cases discussion of advanced disease	Moderator: Florian Lordick, DE
4x15'	4 x Participants clinical case discussion	Faculty
18:10-18:20 10'	Future outlook, conclusion and farewell	Florian Lordick, DE

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion